LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

BACKGROUND: SARS-CoV-2 (COVID-19) has disrupted healthcare service delivery globally. CAB+RPV LA is a novel, long-acting antiretroviral therapy (ART) currently in development and is administered intramuscularly monthly or every 2 months by a healthcare provider. COVID-19 and the resultant restrictio...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Open Forum Infect Dis
Huvudupphovsmän: D'Amico, Ronald, Benn, Paul, McCoig, Cynthia C, Griffith, Sandy, Hudson, Krischan J, Sutton, Kenneth, Harrington, Conn M, Wu, Sterling, Williams, Will, Hove, Kai S, Martin Espanol, Carlos, Fricker, E Jane, Patel, Parul, Margolis, David
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2020
Ämnen:
Late Breaker Abstracts
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777408/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa515.1905
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk